These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38709580)

  • 21. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2016 Jul; 91(7):719-34. PubMed ID: 27291302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the specialist nurse in caring for patients with myeloma.
    Lobban L; Perkins S
    Nurs Stand; 2013 Oct 2-8; 28(5):37-41. PubMed ID: 24093415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
    Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
    Kumar SK; Callander NS; Alsina M; Atanackovic D; Biermann JS; Chandler JC; Costello C; Faiman M; Fung HC; Gasparetto C; Godby K; Hofmeister C; Holmberg L; Holstein S; Huff CA; Kassim A; Liedtke M; Martin T; Omel J; Raje N; Reu FJ; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Weber D; Yahalom J; Shead DA; Kumar R
    J Natl Compr Canc Netw; 2017 Feb; 15(2):230-269. PubMed ID: 28188192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How I manage the toxicities of myeloma drugs.
    Delforge M; Ludwig H
    Blood; 2017 Apr; 129(17):2359-2367. PubMed ID: 28275090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
    Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
    Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
    Boyapati RK; Torres J; Palmela C; Parker CE; Silverberg OM; Upadhyaya SD; Nguyen TM; Colombel JF
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012540. PubMed ID: 29756637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
    Fawole A; Abonour R; Stender M; Shatavi S; Gaikazian S; Anderson J; Jaiyesimi I
    Leuk Lymphoma; 2015 Jan; 56(1):34-41. PubMed ID: 24564573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Common complaints, difficult diagnosis: multiple myeloma.
    Dvorak C
    J Am Acad Nurse Pract; 2006 May; 18(5):190-4. PubMed ID: 16681705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.
    Walter H; Sadeque-Iqbal F; Ulysse R; Castillo D; Fitzpatrick A; Singleton J
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):69-81. PubMed ID: 26571284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
    Rajkumar SV
    Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials.
    Borrelli EP; McGladrigan CG
    J Oncol Pharm Pract; 2021 Jun; 27(4):887-896. PubMed ID: 32686617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Newly diagnosed multiple myeloma.
    Weber DM
    Curr Treat Options Oncol; 2002 Jun; 3(3):235-45. PubMed ID: 12057069
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.